Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Strs Ohio

Strs Ohio decreased its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 4.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,786 shares of the specialty pharmaceutical company’s stock after selling 659 shares during the period. Strs Ohio’s holdings in Jazz Pharmaceuticals were worth $1,675,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Hurley Capital LLC acquired a new position in Jazz Pharmaceuticals during the 1st quarter worth about $25,000. Picton Mahoney Asset Management lifted its stake in Jazz Pharmaceuticals by 2,445.5% during the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock worth $34,000 after acquiring an additional 269 shares in the last quarter. SVB Wealth LLC acquired a new position in Jazz Pharmaceuticals during the 1st quarter worth about $36,000. Hantz Financial Services Inc. lifted its stake in Jazz Pharmaceuticals by 471.4% during the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 297 shares in the last quarter. Finally, Geneos Wealth Management Inc. lifted its stake in Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 137 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on JAZZ shares. Wells Fargo & Company set a $170.00 price target on Jazz Pharmaceuticals in a research report on Wednesday, October 22nd. Royal Bank Of Canada increased their price target on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an “outperform” rating in a research report on Thursday, August 28th. Morgan Stanley set a $183.00 price target on Jazz Pharmaceuticals in a research report on Friday, October 24th. JPMorgan Chase & Co. reduced their price target on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research report on Monday, October 27th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $202.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Fourteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $179.33.

Insider Activity

In other news, Director Bruce C. Cozadd sold 6,000 shares of the company’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the transaction, the director owned 429,973 shares in the company, valued at approximately $55,303,127.26. This represents a 1.38% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In the last ninety days, insiders have sold 11,500 shares of company stock valued at $1,525,280. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $137.82 on Wednesday. The firm’s 50 day moving average is $132.73 and its two-hundred day moving average is $118.85. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. The firm has a market capitalization of $8.36 billion, a P/E ratio of -20.48, a P/E/G ratio of 8.49 and a beta of 0.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same quarter in the previous year, the company posted $5.30 EPS. The company’s quarterly revenue was up 2.1% on a year-over-year basis. Research analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.